我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

脑钠尿肽作为起搏器植入心力衰竭患者筛选指标的临床意义

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2011年第6期
页码:
758-760
栏目:
临床研究
出版日期:
2011-12-25

文章信息/Info

Title:
Brain natriuretic peptide as a screening tool for heart failure in a pacemaker population
作者:
周 缨1; 陈宗建2
1.昆山市第一人民医院心内科，江苏 昆山 215300；2.昆山市第二人民医院心内科，江苏 昆山 215300
Author(s):
ZHOU Ying1;  CHEN Zong-jian2
1.Department of Cardiology, First People’s Hospital of Kunshan, Kunshan 215300, Jiangsu, China; 2.Department of Cardiology, Second People’s Hospital of Kunshan, Kunshan 215300, Jiangsu, China
关键词:
脑钠尿肽; 起搏; 心力衰竭
Keywords:
brain natriuretic peptide;  cardiac pacing;  heart failure
分类号:
R541.61
DOI:
-
文献标识码:
A
摘要:
目的:评价血浆脑钠尿肽（BNP）作为永久性心脏起搏器植入术后心力衰竭的衡量指标的临床意义。方法： 入选行常规植入永久心脏起搏器的患者52例，年齡18～92（70±11）岁。记录患者的诊疗史和检查，心脏超声及收集血液样本，检测BNP。结果： 52例患者中（DDD 12例，VVI 38例，其他 2例）有19例测量左室射血分数（LVEF≤40%）和有心力衰竭症状（纽约心力衰竭分级Ⅱ、Ⅲ或Ⅳ级）。在取诊断界点为BNP≥425 pmol/L时，所有心力衰竭的患者中BNP作为筛选工具有着95%的灵敏度和57%的特异度。这在应用DDD型起搏器时为灵敏度71%，特度87%，而在应用VVI型起搏器为灵敏度90%，特异度69%。结论: BNP作为一种监测指标对于心脏起搏器植入患者心力衰竭的评定是适合而且有帮助的。
Abstract:
AIM:To assess brain natriuretic peptide (BNP) as a screening tool for heart failure in patients with a permanent pacemaker. METHODS: Consecutive patients undergoing a routine permanent pacemaker assessment were enrolled. Patients underwent medical history and examination, echocardiogram and blood sampling for BNP. Analysis was performed in 52 patients (12 DDD, 38 VVI, 2 others; mean age 70±11 years, range: 18-92 years). RESULTS: Nineteen subjects (37%) had heart failure as defined by left ventricular ejection fraction (LVEF) ≤40% and symptoms of heart failure (NYHA class II, III, or IV). At 425 pmol/L, the sensitivity and specificity of screening with BNP were, respectively, 95% and 57% for detecting heart failure in patients under study ［area under the curve (AUC) 0.906, 95% CI 0.860-0.953］. Sensitivity and the specificity were, respectively, 71% and 87% in cases of DDD type pacemakers and were, respectively, 90% and 69% in cases of VVI type pacemakers. CONCLUSION: BNP as an indicator for monitoring patients with cardiac pacemaker implantation is suitable and helpful for assessment of heart failure.

参考文献/References

[1]Dilaveris P.Upgrade to biventricular pacingin patients with pacing-induced heart failure:can resynchronization do the trick[J].Europace,2006,8（5）:352-357.

[2]吴印生.病态窦房结综合征的经典与现代观点[J].临床心血管病杂志,2009,25（3）:238-240.

[3]McDonagh TA,Robb SD,Murdoch DR,et al.Biochemical detection of leftventricular systolic dysfunction[J].Lancet,1998,351（9095）:9-13.

[4]Skanes AC,Krahn AD,Yee R,et al.Progression to chronic atrial fibrillation after pacing:the Canadian Trial of Physiologic Pacing. CTOPP Investigators[J].J Am Coll Cardiol,2001,38(1):167-172.

[5]Wilkoff BL,Cook JR,Epstein AE,et al.Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamberand VVI Implantable Defibrillator (DAVID) Trial[J].JAMA,2002,288(24):3115-3123.

[6]Israel CW,Hohnloser SH.Current status of dual-sensor pacemaker systems for correction of chronotropic incompetence[J].Am J Cardiol,2000,86(9A):86K-94K.

[7]Swedberg K,Cleland J,Dargie H,et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology[J].Eur Heart J,2005,26(11):1115-1140.

[8]Maisel AS,Koon J,Krishnaswamy P,et al.Utility of Bnatriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction[J].Am Heart J,2001,141(3):367-374.

[9]Ichiki H,Oketani N,Hamasaki S,et al.Effect of right ventricular apex pacing on the Tei index and brain natriuretic peptide in patients with a dual-chamber pacemaker[J].Pacing Clin Electrophysiol,2006,29(9):985-990.

备注/Memo

备注/Memo:
收稿日期：2011-02-23.作者简介：周缨，副主任医师Email:zy556@yahoo.com.cn
更新日期/Last Update: 2011-12-27